Plain-English translation of NCT07379190 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people who have suffered a stroke caused by narrowed arteries in the brain. The stroke must have happened between 1 and 7 days before enrollment. Researchers will use advanced MRI imaging to identify exactly what caused your stroke, then give you either combined with two blood-thinning medications, or just the two blood-thinning medications alone.
Most stroke treatments must be given within a few hours of symptom onset, leaving patients who arrive later with limited options. This trial aims to determine whether this medication can safely help people whose strokes were caused by narrowed arteries in the brain, even when treatment begins days after the stroke occurs.
You likely qualify if…
You likely don't qualify if…
If you are chosen for the medication group, you will receive through an IV (intravenous tube) for about 48 hours, along with two daily blood-thinning pills. If you are in the comparison group, you will receive only the two daily pills. Either way, you will take blood-thinning medication for 21 days total, then continue with one blood-thinner long-term. The study involves hospital visits and follow-up appointments to check your recovery and watch for any side effects over several weeks.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
China